Study: MRG007-001/ARR-217-101: An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.